Protective effect of arctigenin against MPP+ and MPTP-induced neurotoxicity

Area of Science:

• Neuroscience
• Pharmacology
• Biochemistry

Background:

• Parkinson's disease (PD) is a neurodegenerative disorder characterized by motor deficits and loss of dopaminergic neurons.
• 1-methyl-4-phenylpyridinium ion (MPP+) and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) are commonly used neurotoxins to model PD in vitro and in vivo.
• Arctigenin, a natural compound, has shown various biological activities, but its neuroprotective potential is not well-established.

Purpose of the Study:

• To investigate the neuroprotective effects of arctigenin against MPP+- and MPTP-induced neurotoxicity.
• To explore the underlying mechanisms of arctigenin's action in cellular and animal models of Parkinson's disease.

Main Methods:

• In vivo study using a MPTP-induced neurotoxicity mouse model to assess motor behavior and neurotransmitter levels (dopamine, GABA).
• In vitro study using cultured human neuroblastoma SH-SY5Y cells treated with MPP+ to evaluate cell viability, apoptosis markers (Bax/Bcl-2, caspase-3), reactive oxygen species (ROS) production, and mitochondrial membrane potential.
• Pretreatment with arctigenin was administered in both models.

Main Results:

• Arctigenin administration improved motor behaviors in the MPTP mouse model.
• Dopamine and gamma-aminobutyric acid (GABA) levels were upregulated by arctigenin in the mouse model.
• In vitro, arctigenin pretreatment attenuated MPP+-induced decrease in cell survival rates.
• Arctigenin reduced apoptosis by decreasing Bax/Bcl-2 ratio and caspase-3 activity.
• Arctigenin exhibited antioxidative effects by reducing ROS production and preserving mitochondrial membrane potential.

Conclusions:

• Arctigenin demonstrates significant neuroprotective activity in both in vitro and in vivo models relevant to Parkinson's disease.
• The findings suggest arctigenin's therapeutic potential for Parkinson's disease through anti-apoptotic and antioxidative mechanisms.
• This study provides the first report of arctigenin's neuroprotective effects, highlighting its promise as a potential therapeutic agent.